Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 11;401(10379):833–842. doi: 10.1016/S0140-6736(22)02465-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Comparison of protection efficacy from past COVID-19 infection versus protection from vaccination (by vaccine type and dose) against re-infection, symptomatic disease, and severe disease for ancestral, alpha, delta, or omicron BA.1 variants

Shading indicates 95% UIs. (A) Comparison between waning of immunity with time of protection conferred by SARS-CoV-2 infection against re-infection with ancestral, alpha, or delta variant versus vaccine protection against primary infection with alpha and delta by type of vaccine and dose. (B) Comparison between waning of immunity with time of protection conferred by SARS-CoV-2 infection against re-infection with omicron variant versus vaccine protection against primary infection with omicron by type of vaccine and dose. (C) Comparison between waning of immunity with time of protection conferred by SARS-CoV-2 infection against symptomatic disease with ancestral, alpha, or delta variant versus vaccine protection against primary infection with alpha and delta by type of vaccine and dose. (D) Comparison between waning of immunity with time of the protection conferred by SARS-CoV-2 infection against symptomatic disease with omicron variant versus vaccine protection against primary infection with omicron by type of vaccine and dose. (E) Comparison between waning of immunity with time of the protection conferred by SARS-CoV-2 infection against severe disease with ancestral, alpha, or delta variant versus vaccine protection against primary infection with alpha and delta by type of vaccine and dose. (F) Comparison between waning of immunity with time of protection conferred by SARS-CoV-2 infection against severe disease with omicron variant versus vaccine protection against primary infection with omicron by type of vaccine and dose. UIs=uncertainty intervals.